Insmed Announces Positive Topline Results from Phase 2b Study of TPIP in PAH Patients

Details

The study met its primary endpoint and all secondary efficacy endpoints. The primary endpoint showed a statistically significant 35% placebo-adjusted reduction from baseline in pulmonary vascular resistance (PVR) (p<0.001). Secondary endpoints demonstrated a 35.5-meter placebo-adjusted improvement in six-minute walk distance (p=0.003) and a 60% placebo-adjusted reduction in N-terminal pro b-type natriuretic peptide (NT-proBNP) concentrations (p<0.001). TPIP was well tolerated, with 84% of patients titrating to at least 480 μg once daily and 75% titrating to the maximum dose of 640 μg once daily. The Company plans to initiate Phase 3 trials for PAH and PH-ILD before the end of 2025 and in early 2026, respectively.

Items reported

Exhibits (2)

About Insmed Inc.

Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.